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Abstract 
MicroRNAs (miRNAs) have been shown in the pathogenesis of human neurological disorders. The study aims to 
identify the involvement of miRNAs in the pathophysiology of narcolepsy. Here, we conducted three independent 
high-throughput analysis of miRNA (miRNA microarray) in peripheral blood from 20 narcolepsy patients who fulfilled 
the criteria compared to 20 healthy controls with validation experiment using quantitative real-time polymerase chain 
reaction (real-time PCR) panels. By analyzing 2805 miRNAs in peripheral blood with microarray we identified 128 miR-
NAs (105 high expression and 23 low expression) that were different in patients with narcolepsy in comparison with 
healthy control. Then we chose six high expression candidates and six low expression candidates of at least twofold 
difference and p value < 0.05 to validate the changes in three independent experiments in vitro using real-time PCR. 
The validation test showed that levels of hsa-mir-1267, hsa-miR-4309, hsa-miR-554, hsa-miR-1272, hsa-miR-4501, hsa-
miR-182-3p were higher, whereas the level of hsa-miR-625-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-197-3p, 
hsa-miR-4522, hsa-miR-493-5p was lower in narcolepsy patients than healthy controls. The levels of 12 miRNAs dif-
fered significantly in peripheral blood from narcolepsy patients which suggested that alterations of miRNAs expres-
sion may be involved in the pathophysiology of narcolepsy.
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Background
Narcolepsy is a life-long sleep disorder characterized 
by excessive daytime sleepiness, cataplexy, sleep paraly-
sis, and hypnagogic hallucinations (Thorpy 2015). Usu-
ally caused by an interplay of genetic and environmental 
factors, narcolepsy is a debilitating condition which can 
affect all aspects of life of which psychosocial function-
ing and quality are reduced (Zeitzer 2013). Recent studies 
shows that the impact of sleep disturbance such as narco-
lepsy is increasingly highlighted on the general outcome 
of a variety of diseases, like epilepsy, Alzheimer, and Par-
kinson (Shan et al. 2015; Economou et al. 2012). Usually 
sleep disorder/disturbance can be hard to diagnose with 
psychosocial consequences (Espie et al. 2014). Nearly all 
patients diagnosed with narcolepsy require lifelong treat-
ment. Unfortunately, till now the pathogenetic molecu-
lar mechanism of narcolepsy is not yet fully understood, 
which showed the difficulty in effective prediction, pre-
vention and treatment.
During the past three decades, molecular analysis for 
disease became more and more important. Especially, 
microRNAs (miRNAs) are considered to be key regu-
lators and valuable biomarker candidates for various 
human pathologies. Recently, alterations in expression 
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of miRNAs in both human and animal model have been 
linked to many forms of disease. miRNAs are a class of 
20- to 22-nt, endogenous, noncoding RNAs. These small 
moleculars usually act as post-transcriptional regulators of 
gene expression by base pairing with their target messen-
ger RNAs (mRNAs) (Igaz and Igaz 2015; Chen et al. 2015). 
Some miRNAs have been identified to regulate neuronal 
processes in the nervous system such as brain morpho-
genesis, neuronal cell differentiation, and transcription 
of neuronal-specific genes (Xue et  al. 2013). The role of 
miRNAs in sleep regulation has been studied in experi-
mental animal models. For example, miRNAs expression 
change in rats’ brain and adipose tissue is resulted from 
sleep deprivation (Davis et al. 2007; Gharib et al. 2012). In 
another study, four miRNAs in mice which are independ-
ent of corticosterone levels are changed because of sleep 
deprivation (Mongrain et al. 2010). Other research shows 
that intraventricular and cortical injection of miRNAs/
anti-miRNAs (inhibitors) into rat brain can alter sleep and 
electroencephalographic (EEG) slow wave activity (Davis 
et al. 2011, 2012). But for human sleep regulation and sleep 
disturbances, it has not been identified.
To explore the general profile of thousands of mole-
cules in parallel in a disease of uncertain origin, different 
methods have been used to profile miRNAs expression, 
including Northern blotting with radio labeled probes, 
oligo-nucleotide microarrays, quantitative PCR-based 
amplification of precursor or mature miRNAs and so on. 
Recently one high-throughput technology named micro-
array is allowed for producing such orders of magnitude 
more data, which addresses the short nature of miRNAs 
and should be able to distinguish between miRNAs that 
differ by as little as a single nucleotide (Chen and Storey 
2014; Alvarez-Mora et al. 2013). Based on result of high-
throughput profiling, it is suggested that qRT PCR is still 
the gold standard for expression validation (Bardelle et al. 
2015; Dedeoglu 2014; Qin et al. 2006).
In the present study we aimed to determine the micro-
RNA profiling in peripheral blood samples from Narco-
lepsy patients and controls, and then validate the significant 
microRNA differences by qRT PCR which is still remained 
gold standard. Our main focus is on potential treatment 
options and novel therapeutic concepts which are in vari-
ous stages of development. The abnormal microRNA 
expression may give insight into the pathophysiological 
mechanisms responsible for the symptoms of these sleep 
disorders, which is for better monitoring disease progress.
Methods
Patient characteristics, clinical features and peripheral 
blood harvest
As shown in Table  1, 20 patients diagnosed with narco-
lepsy were recruited for the initial screening of miRNAs 
in peripheral blood at the Shandong Provincial Hospital 
Affiliated to Shandong University, Shandong, China. Other 
20 healthy controls without medical, neurological, or sleep 
abnormalities were recruited for the initial screening of 
miRNA by advertising for normal volunteers. According 
to International Classification of sleep disorders (ICSD), all 
patients are consistent with the clinical characteristics of 
Narcolepsy. Narcolepsy diagnosis was based on the follow-
ing criteria: (1) excessive daytime sleepiness, (2) mean sleep 
latency <8 min, (3) cataplexy, (4) HLA-DQB1*06:02. Exclu-
sion criteria were the presence of neurological, psychiatric 
or medical disorders. 20 Narcolepsy patients were free of 
antidepressants and stimulants 7–14 days before inclusion. 
Their hypersomnia history was obtained by a semi-struc-
tured interview based on the Stanford Sleep Questionnaire. 
All patients and volunteers provided consent for the use of 
their specimens in research, and this use was approved by 
the institute research ethics committee of the Shandong 
Provincial Hospital Affiliated to Shandong University.
Total RNA isolation and reverse‑transcription
Total RNA was harvested using Trizol (Invitrogen, CA, 
US) and an RNeasy Mini Kit (Qiagen, German) accord-
ing to the manufacturer’s instructions. RNA quality was 
ascertained using an Agilent 2100 bioanalyzer (Agilent 
technologies). 1 μg of total RNA was reverse-transcribed 
and the product (11 μl) was pre-amplified using Megaplex 
PreAmp Primers and DBI Bestar® qPCR RT Kit (Applied 
Biosystems) in a 20 μl PCR reaction. The pre-amplifica-
tion cycling conditions were 37 °C for 60 min and 98 °C 
for 10  min. The pre-amplified cDNA was diluted with 
Table 1 Demographic, clinical, sleep, and  biological data 







Gender (male), n (%) 8 (40 %) 10 (50 %)
Age, years 28.43 (± 6.25) 30.25 (± 5.89)
Body mass index (BMI) 25.70 (± 2.28) 21.20 (± 1.92)
Age of onset, years 19.76 (± 2.95) –
Disease duration 12.30 (± 4.90) –
Epworth sleepiness scale 19.00 (± 2.09) –
Cataplexy, n (%) 18 (90 %) –
Hypnagogic hallucinations, n (%) 18 (90 %) –
Sleep paralysis, n (%) 20 (100 %) –
Awakenings/night 5.93 (± 3.21) –
Sleep latency, sec 296.08 (± 102.25) –
PSGa—Total sleep time (TST), min 398.90 (± 80.21) –
PSGa—Sleep efficiency,  % 87.32 % (± 60.28) –
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0.1 × TE (pH 8.0) to 10 μl and then 1 μl diluted cDNA 
was used in each plate for qRT PCR reactions.
MiRNA microarray analysis
After RNA quan-tification using a Nanodrop 2000 spec-
trophotometer, the samples were labeled using the miR-
CURYHy3/Hy5 Power Labeling Kit and hybridized to 
the miRCURY LNA microRNA Array (v.11.0). The sam-
ples were hybridized using a hybridization station and 
the arrays were scanned with the Axon GenePix 4000B 
Microarray Scanner. The raw intensity of the image was 
read using GenePix Pro V6.0. The intensity of the green 
signal was calculated after background subtraction, and 
four replicated spots for each probe on the same slide 
were averaged. The Median Normalization Method 
was used to obtain ʻNormalized Data’ [Normalized 
Data  =  (foreground-background)/median]. The median 
was defined as the 50 % quantile of microRNA intensity 
that was >50 in all samples after background correc-tion. 
The statistical significance of the differentially expressed 
microRNA was analyzed using the Student’s t test.
Quantitative RT‑PCR of mature miRNAs
Real-time quantification was performed using an Applied 
Bio systems 7500 Sequence Detection system. The 20 µl 
PCR reaction included 1  µl RT product (1:5 dilution), 
0.5  µl Universal reverse primer, 0.5  µl of sense primer, 
and 10 µl mix buffer (DBI Bestar® SybrGreen qPCR mas-
terMix). The reactions were incubated in a 96-well optical 
plate at 94 °C for 2 min, followed by 40 cycles of 94 °C for 
20 s, 58 °C for 20 s and 72 °C for 20 s. All reactions were 
run in triplicate. All primers used are listed in Table 2.
Data analysis
MicroRNA microarray data were analyzed by LC Sci-
ences by subtracting the background and normalizing 
the signals using a locally-weighted regression filter by 
5S rRNA, as described previously. A miRNA was listed 
as detectable when it met at least three criteria: (1) sig-
nal intensity higher than 3  ×  the background standard 
deviation; (2) spot coefficient of variation (CV)  <0.5, in 
which CV was calculated as (standard deviation)/(signal 
intensity); and (3) at least 50 % of the repeated probes had 
a signal 3-times higher than background standard devia-
tion. The miRNA microarray data used the total gene 
signal, which was proportional to the total number of tar-
gets bound by the probes targeting each miRNA. Differ-
entially expressed signals were determine by t-test with 
p < 0.01. To compare qPCR-array and microarray assays, 
the log2 of microarray signals was used.
qRT PCR assay was used to determine the changes in 
the expression of the target miRNAs in peripheral blood 
samples. The change in amplification was normalized to 
the expression of the U6 RNA. The fold change in expres-
sion was calculated for each sample using 2-ΔΔCt, where 
ΔΔCT  =  (Ct target gene-CtU6) narcolepsy–(Ct target 
gene-CtU6) control. A2-ΔΔCt >1.5 or <0.67 was consid-
ered differentially expressed miRNAs.
Results
Differentially expressed microRNAs in narcolepsy patients
miRNA expression profiling studies were conducted 
using the miR-CURY LNA microRNA Array (v. 11.0), 
which contains probes human miRNAs. A total of 2805 
miRNAs were identified. Among these, 105 miRNAs with 
a more than twofold change were differentially expressed 
between the normal peripheral blood and GC, and 23 
miRNAs were significantly low expressed (Fig. 1).
Validation of microRNA microarray results in clinical 
samples by qRT PCR
In order to confirm the results obtained from the miRNA 
microarray, the expression of 12 miRNAs were analyzed 
by qRT PCR in the samples analyzed on the microarray. 
Consistent with the results from the microRNA micro-
array (Fig.  2a, b), hsa-mir-1267, hsa-miR-4309, hsa-
miR-554, hsa-miR-1272, hsa-miR-4501, hsa-miR-182-3p 
were up-regulated and hsa-miR-625-5p, hsa-miR-100-5p, 
hsa-miR-125b-5p, hsa-miR-197-3p, hsa-miR-4522, hsa-
miR-493-5p were down-regulated in each of the periph-
eral blood samples (Fig. 3).
Discussion
Recent data has dem-onstrated the efficacy of miRNAs in 
the prevention, prediction and treat-ment of patients in a 
lot of diseases (Summerer et al. 2015; Tahara et al. 2013; 
Table 2 Sequence of  the primers used for  validation 
of selected miRNAs
















Page 4 of 6Liu et al. SpringerPlus  (2015) 4:812 
Siemelink et al. 2013; Hubaux et al. 2012; Liu et al. 2009). 
We believe miRNAs in narcolepsy might act as molecu-
lar predictors of disease development and management 
outcome. So only one molecular-based treat-ment deci-
sion in these patients may be prob-lematic, not only at 
diagnosis but also at pro-gression, to detect some sensi-
tive gene mutations. This study shows for the first time 
that it is possible to detect differences in a whole miRNAs 
profiling via microarray in plasma from patients with 
sleep disorders (Holm et  al. 2014). In our research, we 
analyzed the expression of 2805 hsa-miRNAs in periph-
eral blood samples for the association between important 
mRNA degradation and clinicopathological data after 
miRNA microarray and validation experi-ments in vitro 
Fig. 1 The cluster analysis of miRNAs expression in peripheral blood 
samples screened by miRNA microarray. Heat map: the horizontal for 
different hsa-miRNAs, two columns for different cohorts. Red for up-
regulated hsa-miRNAs, green for down-regulated hsa-miRNAs, black 
for no differentially expressed hsa-miRNAs. Color shade represents the 
intensity of fluorescence and reflects the level of hsa-miRNAs expres-
sion. The scheme indicated that the clustering properties of gene 
expression in narcolepsy patients were obvious. N normal healthy 
controls; T tested narcolepsy patients
Fig. 2 12 differential hsa-miRNAs related to narcolepsy sensitiv-
ity between cohort narcolepsy patients and healthy controls 
were screened and identified by real-time PCR. a High level of six 
hsa-miRNAs randomly selected for the validation of expression level 
by qRT-PCR is consistent with the result from miRNA microarray; b 
Low level of six hsa-miRNAs randomly selected for the validation of 
expression level by real-time RT-PCR is consistent with the result from 
miRNA microarray
Fig. 3 Validation of 12 hsa-miRNAs using qRT PCR shows hsa-
mir-1267, hsa-miR-4309, hsa-miR-554, hsa-miR-1272, hsa-miR-4501, 
hsa-miR-182-3p were up-regulated and hsa-miR-625-5p, hsa-miR-
100-5p, hsa-miR-125b-5p, hsa-miR-197-3p, hsa-miR-4522, hsa-miR-
493-5p were down-regulated in each of the peripheral blood samples 
from narcolepsy patients. Black folder change of narcolepsy patients/
control, white folder change of control/narcolepsy patients
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were performed. Microarray results showed that plasma 
levels of the 105 hsa-miRNAs highly expressed and 23 
hsa-miRNAs had low expression which suggested that 
they may be asso-ciated with narcolepsy status. Among 
these miRNAs with significant change, 12 hsa-miRNAs 
were validated by qRT PCR which showed that hsa-
mir-1267, hsa-miR-4309, hsa-miR-554, hsa-miR-1272, 
hsa-miR-4501, hsa-miR-182-3p had significantly high 
expression and hsa-miR-625-5p, hsa-miR-100-5p, hsa-
miR-125b-5p, hsa-miR-197-3p, hsa-miR-4522, hsa-miR-
493-5p had significantly low expression in each of the 
peripheral blood samples. Our results suggested a poten-
tial therapeutic target of miRNAs for narcolepsy.
As we know, usually 3′ UTR of genes are targeted by 
miRNA resulting in a significant reduction of full-length 
protein. So miRNAs with remarkable change in silico 
analysis may target some important genes which play an 
important role in narcolepsy (Holm et  al. 2014). Some 
silico analysis implied that some important molecular 
signaling pathway such as IP3 pathway, IGF1R path-
way, cAMP pathway may be associated with cognitive 
enhancement in animal models of brain disease (Jellen 
et  al. 2015). Based on previous research, it is suggested 
that TAC1, PENK and SOCS2 might be intimately con-
nected with the excessive daytime sleepiness not only 
in dogs, but also in other species, possibly including 
humans (Lindberg et  al. 2007). Other studies revealed 
that the diagnosis of narcolepsy but not CPT1B expres-
sion level was associated with abnormally and signifi-
cantly low acylcarnitine levels (Miyagawa et  al. 2011). 
Recently a new study discovered that HLA risk loci and 
protective variants for narcolepsy, which were independ-
ent of the well-established HLA-DQ effects in narco-
lepsy (Ollila et al. 2015). And function of tbx3 in neurons 
may be effective in populations with sleep abnormalities 
(Eriksson and Mignot 2009). Further studies are required 
to clarify the relationship between miRNAs we screened 
out and those important genes during narcolepsy.
In conclusion, we have identified 12 aberrant miR-
NAs (hsa-mir-1267, hsa-miR-4309, hsa-miR-554, 
hsa-miR-1272, hsa-miR-4501, hsa-miR-182-3p, hsa-
miR-625-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-
miR-197-3p, hsa-miR-4522, hsa-miR-493-5p) in plasma 
from patients with sleep disorder. According to previous 
research, some miRNAs we screened out were involved 
in some other functions. For example, miR-625-5p may 
act as one of potential mediators of hypoxic response 
in soft tissue sarcomas (STS); miR-100-5p appeared to 
be important to regulation some gene expression dur-
ing GC reaction. However, the biological significance of 
them in narcolepsy remains unclear. It is proposed that 
exploring the molecular mechanism of these miRNAs 
and their targets might increase our understanding of 
the pathogenesis of narcolepsy. Thus our results provide 
a new perspective on investigating sleep disorders, and 
offer a new approach to identifying relevant pathways in 
the pathogenesis of narcolepsy.
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